↓ Skip to main content

Discounting the Recommendations of the Second Panel on Cost-Effectiveness in Health and Medicine

Overview of attention for article published in PharmacoEconomics, December 2016
Altmetric Badge

About this Attention Score

  • In the top 25% of all research outputs scored by Altmetric
  • High Attention Score compared to outputs of the same age (91st percentile)
  • High Attention Score compared to outputs of the same age and source (92nd percentile)

Mentioned by

news
1 news outlet
blogs
1 blog
twitter
12 X users
facebook
1 Facebook page

Citations

dimensions_citation
24 Dimensions

Readers on

mendeley
76 Mendeley
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Title
Discounting the Recommendations of the Second Panel on Cost-Effectiveness in Health and Medicine
Published in
PharmacoEconomics, December 2016
DOI 10.1007/s40273-016-0482-0
Pubmed ID
Authors

Mike Paulden, James F. O’Mahony, Christopher McCabe

Abstract

Twenty years ago, the "Panel on Cost-effectiveness in Health and Medicine" published a landmark text setting out appropriate methods for conducting cost-effectiveness analyses of health technologies. In the two decades since, the methods used for economic evaluations have advanced substantially. Recently, a "second panel" (hereafter "the panel") was convened to update the text and its recommendations were published in November 2016. The purpose of this paper is to critique the panel's updated guidance regarding the discounting of costs and health effects. The advances in discounting methodology since the first panel include greater theoretical clarity regarding the specification of discount rates, how these rates vary with the analytical perspective chosen, and whether the healthcare budget is constrained. More specifically, there has been an important resolution of the debate regarding the conditions under which differential discounting of costs and health effects is appropriate. We show that the panel's recommendations are inconsistent with this recent literature. Importantly, the panel's departures from previously published findings do not arise from an alternative interpretation of theory; rather, we demonstrate that this is due to fundamental errors in methodology and logic. The panel also failed to conduct a formal review of relevant empirical evidence. We provide a number of suggestions for how the panel's recommendations could be improved in future.

X Demographics

X Demographics

The data shown below were collected from the profiles of 12 X users who shared this research output. Click here to find out more about how the information was compiled.
Mendeley readers

Mendeley readers

The data shown below were compiled from readership statistics for 76 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Unknown 76 100%

Demographic breakdown

Readers by professional status Count As %
Student > Ph. D. Student 9 12%
Student > Master 8 11%
Researcher 7 9%
Student > Doctoral Student 6 8%
Unspecified 4 5%
Other 13 17%
Unknown 29 38%
Readers by discipline Count As %
Medicine and Dentistry 14 18%
Economics, Econometrics and Finance 7 9%
Nursing and Health Professions 5 7%
Unspecified 4 5%
Agricultural and Biological Sciences 2 3%
Other 11 14%
Unknown 33 43%
Attention Score in Context

Attention Score in Context

This research output has an Altmetric Attention Score of 22. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 01 June 2020.
All research outputs
#1,727,810
of 25,374,917 outputs
Outputs from PharmacoEconomics
#98
of 1,992 outputs
Outputs of similar age
#33,835
of 420,134 outputs
Outputs of similar age from PharmacoEconomics
#2
of 27 outputs
Altmetric has tracked 25,374,917 research outputs across all sources so far. Compared to these this one has done particularly well and is in the 93rd percentile: it's in the top 10% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 1,992 research outputs from this source. They typically receive more attention than average, with a mean Attention Score of 7.6. This one has done particularly well, scoring higher than 95% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 420,134 tracked outputs that were published within six weeks on either side of this one in any source. This one has done particularly well, scoring higher than 91% of its contemporaries.
We're also able to compare this research output to 27 others from the same source and published within six weeks on either side of this one. This one has done particularly well, scoring higher than 92% of its contemporaries.